While treatment response is routinely monitored using periodic measurement of serum PSA, the long interval between the first rise in PSA reading and diagnosis of localized recurrent disease can be prolonged, increasing the risk of development of metastatic disease. This evidence concerns the gene KLK3 and metastatic neoplasm.